Comparing BTK inhibitors in relapsed/refractory CLL; unraveling the genetic background of the AnWj-negative blood type; rapid adaptation of CLL cells to venetoclax

Discover the latest advancements in CLL treatment as researchers compare BTK inhibitors, revealing zanubrutinib's promising edge over ibrutinib. Unravel the genetic mysteries behind the rare AnWj-negative blood type, shedding light on its unique characteristics. Finally, explore how CLL cells cleverly adapt to venetoclax therapy, highlighting the crucial roles of BCL-2 and BAFF in their survival. This unique blend of science sheds new light on cancer treatment and genetic research!